Omeros (NASDAQ:OMER) Upgraded to "Hold" by StockNews.com

Omeros (NASDAQ:OMER - Get Free Report) was upgraded by equities research analysts at StockNews.com from a "sell" rating to a "hold" rating in a research note issued to investors on Wednesday.

Omeros Trading Up 3.3 %

Shares of NASDAQ:OMER traded up $0.10 during midday trading on Wednesday, hitting $3.15. The company had a trading volume of 332,799 shares, compared to its average volume of 596,572. The firm has a fifty day simple moving average of $3.87 and a 200 day simple moving average of $2.97. The stock has a market cap of $198.02 million, a price-to-earnings ratio of 9.84 and a beta of 1.34. Omeros has a 12 month low of $0.92 and a 12 month high of $7.80.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. First Trust Advisors LP lifted its holdings in Omeros by 2.4% during the fourth quarter. First Trust Advisors LP now owns 172,755 shares of the biopharmaceutical company's stock worth $565,000 after acquiring an additional 4,130 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Omeros by 1.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 312,409 shares of the biopharmaceutical company's stock worth $706,000 after acquiring an additional 4,170 shares in the last quarter. Ameritas Investment Partners Inc. bought a new position in Omeros during the second quarter worth about $27,000. Tower Research Capital LLC TRC lifted its holdings in Omeros by 199.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,069 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 5,378 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Omeros by 3.0% in the first quarter. Bank of New York Mellon Corp now owns 205,160 shares of the biopharmaceutical company's stock valued at $1,233,000 after purchasing an additional 5,938 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.